Leptin deficient rats develop nonalcoholic steatohepatitis with unique disease progression
Ping Lu, Guang Yang, Wen He, Wanwan Wu, Lingbin Qi, Shijun Shen, Junhua Rao, Guoping FaniD, Zhigang XueiD, Peng Zhang, Cizhong Jiang, Xianmin Zhu
Abstract
Nonalcoholic steatohepatitis (NASH) is an aggressive liver disease threatening public health, however its natural history is poorly understood. Unlike ob/ob mice, Lep{triangleup}I14/{triangleup}I14 rats develop unique NASH phenotype with steatosis, lymphocyte infiltration and ballooning after postnatal week 16. Using Lep{triangleup}I14/{triangleup}I14 rats as NASH model, we studied the natural history of NASH progression by performing an integrated analysis of hepatic transcriptome from postnatal week 4 to 48. Leptin deficiency results in a robust increase in expression of genes encoding 9 rate-limiting enzymes in lipid metabolism such as ACC and FASN. However, genes in positive regulation of inflammatory response are highly expressed at week 16 and then remain the steady elevated expression till week 48. The high expression of cytokines and chemokines including CCL2, TNF, IL6 and IL1{beta} is correlated with the phosphorylation of several key molecules in pathways such as JNK and NF-{kappa}B. Meanwhile, we observed cell infiltration of MPO+ neutrophils, CD8+ T cells, CD68+ hepatic macrophages and CCR2+ inflammatory monocyte-derived macrophages, together with macrophage polarization from M2 to M1. Importantly, Lep{triangleup}I14/{triangleup}I14 rats share more homologous genes with NASH patients than previously established mouse models and crab eating monkeys with spontaneous hepatic steatosis. Transcriptomic analysis showed that many drug targets in clinical trials can be evaluated in Lep{triangleup}I14/{triangleup}I14 rats.\n\nConclusionWe characterize Lep{triangleup}I14/{triangleup}I14 rats as a unique NASH model by performing a long-term (i.e., 4 to 48 postnatal weeks) integrated transcriptomic analysis. This work reveal the temporal dynamics of hepatic gene expression in lipid metabolism and inflammation, and shed light on understanding the natural history of NASH in human beings.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of non-alcoholic steatohepatitis
T. Duparc, F. Briand, … L. O. Martinez·bioRxiv·May 17, 2019
- Autocrine IL11 cis-signaling in hepatocytes is an initiating nexus between lipotoxicity and non-alcoholic steatohepatitis
Jinrui Dong, Sivakumar Viswanathan, … Anissa Anindya Widjaja·Nature CommunicationsPeer-reviewed·Jan 4, 2021
- Longitudinal analysis of a dietary mouse model of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
M. M. Saenz, J. C. McDonough, … L. S. Trevino·bioRxiv·May 19, 2023
- Hepatocyte-specific loss of LAP2α protects against diet-induced hepatic steatosis and steatohepatitis in male mice
K. K. Upadhyay, E.-Y. K. Choi, … G. F. Brady·bioRxiv·Mar 18, 2022
- Downregulation of CYP7B1 caused by lipotoxicity associates with the progression of non-alcoholic steatohepatitis
Y. Watanabe, K. Kinoshita, … R. Sato·bioRxiv·May 10, 2023
- Hepatocyte PPARγ contributes to the progression of non-alcoholic steatohepatitis in male and female obese mice.
S. M. Lee, J. Muratalla, … J. Cordoba-Chacon·Cellular and Molecular Life SciencesPeer-reviewed·Jan 11, 2023